Showing 26,601 - 26,620 results of 26,807 for search '(( 5 ((nn decrease) OR (teer decrease)) ) OR ( 50 ((ms decrease) OR (a decrease)) ))', query time: 0.70s Refine Results
  1. 26601

    Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF by Jiachuan Xiong (748476)

    Published 2021
    “…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”
  2. 26602

    DataSheet_1_WASp Deficiency Selectively Affects the TCR Diversity of Different Memory T Cell Subsets in WAS Chimeric Mice.zip by Wenyan Li (255305)

    Published 2022
    “…Bioinformatic analyses showed that compared with wild type (WT), WAS knock out (KO)-CD4<sup>+</sup> TEM cells exhibited increased Simpson index and decreased D50 index (P <0.05); The rank abundance curve of KO-CD4<sup>+</sup> TEM cells was shorter and steeper than that of WT, and the angle of <sup>q</sup>D and q in KO-CD4<sup>+</sup> TEM cells was lower than that of WT, while these indexes showed few changes between WT and KO chimeric mice in the CD8<sup>+</sup>TCM population. …”
  3. 26603

    Acceleration of nephron maturation and reduction of cap mesenchyme at E18.5 in Bmp7 knockout kidneys. by Mayumi Tomita (450540)

    Published 2013
    “…<p>(<b>A</b>) Pregnant mothers bearing Bmp7<sup>LacZ/fl</sup>;Gt(ROSA)26Sor<sup>CreERT2</sup> and Bmp7<sup>+/fl</sup>;Gt(ROSA)26Sor<sup>CreERT2</sup> embryos were administered tamoxifen at E12.5, and sacrificed at E18.5. …”
  4. 26604

    Northern blot analysis of riRNA. by Hiraku Takada (3599702)

    Published 2016
    “…The level of rRNA markedly decreased in the stationary phase. [C] <i>E</i>. <i>coli</i> BW25113 was grown in M9-glucose medium, and in the middle of exponential phase, total RNA was prepared using Isogen and subjected to Northern blot analysis using a series of Northern probes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>, probes N01 to N10). riRNA was detected using two specific probes, probe-N3 and probe-N4 (for probes see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>; and for primers used for amplification of these probes, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.s005" target="_blank">S2 Table</a>). …”
  5. 26605

    <strong>Bull trout streamflow and temperature linear SCR model</strong> by Patti Wohner (16398345)

    Published 2023
    “…These extremes provided a unique opportunity to retrospectively compare bull trout survival and migration under potential climate change scenarios. …”
  6. 26606

    Robotic-Assisted Median Arcuate Ligament Release With Celiac Artery Lysis and Celiac Ganglion Neurolysis by G. Kimble Jett (6509428)

    Published 2020
    “…<a href="https://doi.org/10.1016/j.jvs.2008.12.078"><em>J Vasc Surg</em>. 2009;50:124-133.…”
  7. 26607

    Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  8. 26608

    Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  9. 26609

    Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  10. 26610

    Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  11. 26611

    Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  12. 26612

    Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

    Published 2025
    “…Yellow: increased, dark grey: decreased, light grey: unchanged. (M) Bar plots show the percentage of glomeruli exhibiting a change in response for cued vs. un-cued trials. …”
  13. 26613

    Phenotypic characterization of <i>CsIVP</i>-RNAi transgenic plants. by Shuangshuang Yan (798064)

    Published 2020
    “…Scale bars represent 2 cm in panels A, D–J, and P; 2 mm in panel K; 200 μm in panels L–O; 50 μm in panels L’–O’; and 100 μm in panels R–U. …”
  14. 26614

    P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab). by Hong Yan Huang (20135965)

    Published 2024
    “…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”
  15. 26615

    Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  16. 26616

    Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  17. 26617

    Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  18. 26618

    Living 3,4-Polymerization of Isoprene by Cationic Rare Earth Metal Alkyl Complexes Bearing Iminoamido Ligands by Gaixia Du (1631482)

    Published 2011
    “…The sterically crowded complexes <b>1</b>−<b>3</b> give a mixture of 3,4- and <i>trans</i>-1,4-polyisoprenes (3,4-selectivities: 48−82%, <i>trans</i>-1,4-selectivities: 50−17%), whereas the less sterically demanding complexes <b>4</b>−<b>6</b> show high 3,4-selectivities (3,4-selectivities: 90−100%). …”
  19. 26619

    DataSheet1_Insights into the reactivity and lithium plating mechanisms of ultra-thin metal oxide coatings for anode-free solid-state lithium metal batteries.docx by Michael J. Counihan (4852780)

    Published 2023
    “…Increasing Al<sub>2</sub>O<sub>3</sub> thickness decreases the practical current density compared to unmodified Cu (30 µA/cm<sup>2</sup>), but increasing ZnO thicknesses can double or triple this value. …”
  20. 26620

    Table_14_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”